Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 extension study of NS-035 in Fukuyama-type congenital muscular dystrophy
jRCT2031250857Phase 1Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NS-035 in Fukuyama congenital muscular dystrophy (FCMD), sponsored by Nippon Shinyaku. Primary endpoints: Adverse events, Physical and neurological examination and 11 more. Started Apr 2026; status: recruiting.
02
Drugs
NS-035
03
Conditions
Fukuyama congenital muscular dystrophy (FCMD)
Beyond the preview
Go deeper on jRCT2031250857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250857.